The objective of Present work was the development of sustained release tablet dosage form or the controlled release dosage form of a new carbapenum an antibiotic, an antimicrobial called as Faropenem Sodium. A new controlled release drug delivery system or sustained drug delivery oral Carbapenum “Faropenum” which act as an Antimicrobial, Antibiotic pharmaceutical. It works against broad spectrum aerobic, anaerobic gram positive and gram negative bacteria along with the Pseudomonas aeruginosa. The aim of the research is to use l-threonine as the material along with the formulation and evaluation of the new beta lactam antibiotic or can be called as the new carbapenum. The formulation was evaluated for the following effect of extended release polymer, effect of formula reproducibility, effect of pH of dissolution media on drug release and effect of storage under ICH accelerated conditions. It not only propagates the section but also works on the bacteria by inhibiting the synthesis of bacterial cell wall. The formulation is having the different pharmacokinetic property, effective in the treatment of various diseased conditions like: respiratory tract, urinary tract, ophthalmic, pulmonary, community acquired pneumonia, pyelonephritis, Acute bacterial sinusitis, Community acquired pneumonia, Acute exacerbations of chronic bronchitis, Uncomplicated skin and skin structure infection, Otitis externa, Sinusitis, Tympanitis, Prostatitis, Cystitis, Tonsillitis, Pharyngitis, Bartholin’s gland infection and adnexitis , Lymphangitis, Folliculitis, Pustular acne, Secondary infection of external wound or surgical wound, Subcutaneous abscesses.